Table 1_The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy.docx

Table 1_The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy.docx

<p>Antibody-drug conjugates (ADCs) offer targeted cancer therapy by delivering cytotoxic agents directly to tumor cells. However, challenges such as relapse, resistance, and diverse patient needs drive ongoing innovation in ADC development. Exploration of new small-molecule toxins with unique...

Full description

Saved in:
Bibliographic Details
Main Author: Huihui Guo (116685) (author)
Other Authors: Hongsheng Xie (716868) (author), Yuanyuan Huang (671992) (author), Junxiang Jia (18203483) (author), Xiangfei Kong (1909192) (author), Qingliang Yang (493947) (author), Shun Gai (20697275) (author), Wenjun Li (41954) (author), Lu Bai (343118) (author), Lingli Zhang (160932) (author), Xiaoxiao Chen (1673935) (author), Zhicang Ye (1520740) (author), Hangbo Ye (18215725) (author), Linyao Zhao (11183196) (author), Yifang Xu (18215728) (author), Yong Du (86188) (author), Xiuzhen Zhang (2309947) (author), Miaomiao Chen (763128) (author), Xiaomai Zhou (20317484) (author), Robert Y. Zhao (2196925) (author)
Published: 2025
Subjects:
Pharmacology
Tub114
DX126-262
tubulysin B analog
target-specific delivery
HER2
therapeutic window
ADC
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items